PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 10423959-8 1999 Diverse cytokines are known to play an important role in anti-TB cell-mediated immunity, including IL-2, IL-12, IL-18 and IFN-gamma. Terbium 62-64 interleukin 2 Homo sapiens 99-103 34679041-11 2021 The transcription levels of IL-2, IFN-gamma, IL-4 and IL-10 cytokines in the TB-Cap, TB-Cap-CD154 and TB-Cap-GM-CSF groups were significantly higher than those in the PBS and recombinant vaccine groups (p < 0.0001). Terbium 77-79 interleukin 2 Homo sapiens 28-32 34679041-11 2021 The transcription levels of IL-2, IFN-gamma, IL-4 and IL-10 cytokines in the TB-Cap, TB-Cap-CD154 and TB-Cap-GM-CSF groups were significantly higher than those in the PBS and recombinant vaccine groups (p < 0.0001). Terbium 102-104 interleukin 2 Homo sapiens 28-32 2506411-3 1989 Moreover, a strict relationship between Tac antigen expression and ability of exogenous IL-2 to enhance bulk culture cell proliferation was observed in Dis-TB patients. Terbium 156-158 interleukin 2 Homo sapiens 88-92 33317988-8 2021 In Nil tubes, CCL5/RANTES, TNF-alpha, PDGF-BB, and IL-2 levels were significantly higher in the active TB group. Terbium 103-105 interleukin 2 Homo sapiens 51-55 28061954-11 2017 Cytokines such as IL-2 and IL-10 may serve as biomarkers for distinguishing ATB from LTBI and healthy control and may contribute to intervention and improvement in TB diagnosis. Terbium 77-79 interleukin 2 Homo sapiens 18-22 32125282-4 2020 Here, we evaluated the DNA methylation status of TB patients and their asymptomatic household contacts demonstrating that TB patients have DNA hyper-methylation of the IL-2-STAT5, TNF-NF-kappaB and IFN-gamma signaling pathways. Terbium 49-51 interleukin 2 Homo sapiens 168-172 32125282-4 2020 Here, we evaluated the DNA methylation status of TB patients and their asymptomatic household contacts demonstrating that TB patients have DNA hyper-methylation of the IL-2-STAT5, TNF-NF-kappaB and IFN-gamma signaling pathways. Terbium 122-124 interleukin 2 Homo sapiens 168-172 32700645-6 2020 The pooled sensitivity, specificity, PLR, NLR,DOR and AUROCof IL-2 were separately as 87%, 98%, 34.78, 0.14, 256.41 and 0.98, indicating a very powerful differentiating ability of IL-2 for LTBI from non-TB controls.For differentiating ATB from LTBI, the pooled sensitivity, specificity, PLR, NLR,DOR and AUROCof IL-2 were 83%, 76%, 3.41, 0.22, 15.47 and 0.87, respectively, suggesting a good differentiating ability of IL-2.Conclusions: These findings showed that IL-2 is a powerful marker for differentiating LTBI from non-TB controls and a good marker for differentiating ATB from LTBI individuals. Terbium 190-192 interleukin 2 Homo sapiens 180-184 32700645-6 2020 The pooled sensitivity, specificity, PLR, NLR,DOR and AUROCof IL-2 were separately as 87%, 98%, 34.78, 0.14, 256.41 and 0.98, indicating a very powerful differentiating ability of IL-2 for LTBI from non-TB controls.For differentiating ATB from LTBI, the pooled sensitivity, specificity, PLR, NLR,DOR and AUROCof IL-2 were 83%, 76%, 3.41, 0.22, 15.47 and 0.87, respectively, suggesting a good differentiating ability of IL-2.Conclusions: These findings showed that IL-2 is a powerful marker for differentiating LTBI from non-TB controls and a good marker for differentiating ATB from LTBI individuals. Terbium 190-192 interleukin 2 Homo sapiens 180-184 32700645-6 2020 The pooled sensitivity, specificity, PLR, NLR,DOR and AUROCof IL-2 were separately as 87%, 98%, 34.78, 0.14, 256.41 and 0.98, indicating a very powerful differentiating ability of IL-2 for LTBI from non-TB controls.For differentiating ATB from LTBI, the pooled sensitivity, specificity, PLR, NLR,DOR and AUROCof IL-2 were 83%, 76%, 3.41, 0.22, 15.47 and 0.87, respectively, suggesting a good differentiating ability of IL-2.Conclusions: These findings showed that IL-2 is a powerful marker for differentiating LTBI from non-TB controls and a good marker for differentiating ATB from LTBI individuals. Terbium 190-192 interleukin 2 Homo sapiens 180-184 32700645-6 2020 The pooled sensitivity, specificity, PLR, NLR,DOR and AUROCof IL-2 were separately as 87%, 98%, 34.78, 0.14, 256.41 and 0.98, indicating a very powerful differentiating ability of IL-2 for LTBI from non-TB controls.For differentiating ATB from LTBI, the pooled sensitivity, specificity, PLR, NLR,DOR and AUROCof IL-2 were 83%, 76%, 3.41, 0.22, 15.47 and 0.87, respectively, suggesting a good differentiating ability of IL-2.Conclusions: These findings showed that IL-2 is a powerful marker for differentiating LTBI from non-TB controls and a good marker for differentiating ATB from LTBI individuals. Terbium 190-192 interleukin 2 Homo sapiens 180-184 32700645-6 2020 The pooled sensitivity, specificity, PLR, NLR,DOR and AUROCof IL-2 were separately as 87%, 98%, 34.78, 0.14, 256.41 and 0.98, indicating a very powerful differentiating ability of IL-2 for LTBI from non-TB controls.For differentiating ATB from LTBI, the pooled sensitivity, specificity, PLR, NLR,DOR and AUROCof IL-2 were 83%, 76%, 3.41, 0.22, 15.47 and 0.87, respectively, suggesting a good differentiating ability of IL-2.Conclusions: These findings showed that IL-2 is a powerful marker for differentiating LTBI from non-TB controls and a good marker for differentiating ATB from LTBI individuals. Terbium 203-205 interleukin 2 Homo sapiens 180-184 32700645-6 2020 The pooled sensitivity, specificity, PLR, NLR,DOR and AUROCof IL-2 were separately as 87%, 98%, 34.78, 0.14, 256.41 and 0.98, indicating a very powerful differentiating ability of IL-2 for LTBI from non-TB controls.For differentiating ATB from LTBI, the pooled sensitivity, specificity, PLR, NLR,DOR and AUROCof IL-2 were 83%, 76%, 3.41, 0.22, 15.47 and 0.87, respectively, suggesting a good differentiating ability of IL-2.Conclusions: These findings showed that IL-2 is a powerful marker for differentiating LTBI from non-TB controls and a good marker for differentiating ATB from LTBI individuals. Terbium 203-205 interleukin 2 Homo sapiens 180-184 32700645-6 2020 The pooled sensitivity, specificity, PLR, NLR,DOR and AUROCof IL-2 were separately as 87%, 98%, 34.78, 0.14, 256.41 and 0.98, indicating a very powerful differentiating ability of IL-2 for LTBI from non-TB controls.For differentiating ATB from LTBI, the pooled sensitivity, specificity, PLR, NLR,DOR and AUROCof IL-2 were 83%, 76%, 3.41, 0.22, 15.47 and 0.87, respectively, suggesting a good differentiating ability of IL-2.Conclusions: These findings showed that IL-2 is a powerful marker for differentiating LTBI from non-TB controls and a good marker for differentiating ATB from LTBI individuals. Terbium 203-205 interleukin 2 Homo sapiens 180-184 32700645-6 2020 The pooled sensitivity, specificity, PLR, NLR,DOR and AUROCof IL-2 were separately as 87%, 98%, 34.78, 0.14, 256.41 and 0.98, indicating a very powerful differentiating ability of IL-2 for LTBI from non-TB controls.For differentiating ATB from LTBI, the pooled sensitivity, specificity, PLR, NLR,DOR and AUROCof IL-2 were 83%, 76%, 3.41, 0.22, 15.47 and 0.87, respectively, suggesting a good differentiating ability of IL-2.Conclusions: These findings showed that IL-2 is a powerful marker for differentiating LTBI from non-TB controls and a good marker for differentiating ATB from LTBI individuals. Terbium 203-205 interleukin 2 Homo sapiens 180-184 31472402-4 2020 TB-KDM individuals exhibit significantly higher levels of IFNgamma, IL-2, TNFalpha, IL-17A, IL-1alpha, IL-1beta and IL-6 in comparison to TB-NDM, TB alone and DM alone individuals. Terbium 0-2 interleukin 2 Homo sapiens 68-72 31472402-7 2020 TB-NDM individuals are also characterized by significantly diminished TB-antigen stimulated levels of IFNgamma, IL-2, TNFalpha, IL-17A, IL-17F, IL-1alpha, IL-1beta and/or IL-6 at pre-treatment and at 2 months of ATT and IFNgamma, IL-2, IL-1alpha and IL-1beta at post-treatment. Terbium 0-2 interleukin 2 Homo sapiens 112-116 31472402-7 2020 TB-NDM individuals are also characterized by significantly diminished TB-antigen stimulated levels of IFNgamma, IL-2, TNFalpha, IL-17A, IL-17F, IL-1alpha, IL-1beta and/or IL-6 at pre-treatment and at 2 months of ATT and IFNgamma, IL-2, IL-1alpha and IL-1beta at post-treatment. Terbium 0-2 interleukin 2 Homo sapiens 231-235 31454491-10 2019 In conclusion, IFN-gamma/IL-2 FluoroSpot assay is conducive for the diagnosis of ATB in patients with positive T-SPOT.TB results. Terbium 82-84 interleukin 2 Homo sapiens 25-29 26611774-8 2016 In contrast, TB-IRIS patients had significantly greater early increases in the frequency of tuberculosis-specific polyfunctional IFN-gamma(+)/IL-2(+)/TNF-alpha(+) CD4(+) T-cells on ART (P = .02); each quartile increase in the percentage of these cells was independently associated with a 2.8-fold increased risk of TB-IRIS (95% confidence interval, 1.1 to 7.5-fold). Terbium 13-15 interleukin 2 Homo sapiens 142-146 26765255-13 2016 Pregnant women with IGRA(+)/TST(-) discordance had less IFN-gamma and IL-2 than those with concordant-positive results and may represent an especially high-risk subset for the development of active TB postpartum. Terbium 198-200 interleukin 2 Homo sapiens 70-74 23272100-10 2012 Combining the QFT with IP-10 and IL-2 could increase the detection accuracy of active TB over the QFT alone. Terbium 86-88 interleukin 2 Homo sapiens 33-37 27238179-2 2016 Three major cytokines involved in TB immunopathogenesis include IL-2, IL-4 and IL-10. Terbium 34-36 interleukin 2 Homo sapiens 64-68 27238179-10 2016 Circulating IL-4 and IL-10 levels were significantly decreased whilst serum IL-2 level was significantly increased in patients with MDR TB compared to non-MDR TB. Terbium 136-138 interleukin 2 Homo sapiens 76-80 27238179-10 2016 Circulating IL-4 and IL-10 levels were significantly decreased whilst serum IL-2 level was significantly increased in patients with MDR TB compared to non-MDR TB. Terbium 159-161 interleukin 2 Homo sapiens 76-80 25504009-1 2015 The main objective of the study was to evaluate whether in vitro QuantiFERON-TB Gold In-Tube (QFT-GIT) assay antigen-specific IL-1beta, TNF-alpha, IL-2, IL-6, IL-8 and IL-12 (p40) production is associated with active TB. Terbium 77-79 interleukin 2 Homo sapiens 147-151 26245995-5 2015 RESULTS: The discrimination performance (assessed by the area under ROC curve) for IL-2 following stimulation with recombinant PE35 and PPE68 between LTBI and patients with active TB were 0.837 [95 % confidence interval (CI) 0.72-0.97] for LTBI diagnosis and 0.75 (95 % CI 0.63-0.89) for active TB diagnosis, respectively. Terbium 151-153 interleukin 2 Homo sapiens 83-87 26245995-5 2015 RESULTS: The discrimination performance (assessed by the area under ROC curve) for IL-2 following stimulation with recombinant PE35 and PPE68 between LTBI and patients with active TB were 0.837 [95 % confidence interval (CI) 0.72-0.97] for LTBI diagnosis and 0.75 (95 % CI 0.63-0.89) for active TB diagnosis, respectively. Terbium 180-182 interleukin 2 Homo sapiens 83-87 26245995-6 2015 Applying the 6.4 pg/mL cut-off for IL-2 induced by PE35 in the present study population resulted in sensitivity of 78 %, specificity of 83 %, PPV of 83 % and NPV of 78 % for the discrimination of active TB and LTBI. Terbium 203-205 interleukin 2 Homo sapiens 35-39 22961735-6 2012 The single subset distinguishing best between active pulmonary TB and high TB exposure was CD154(+) /TNF-alpha(+) / IFN-gamma(-) /IL-2(-) /degranulation(-) (AUROC 0.90). Terbium 63-65 interleukin 2 Homo sapiens 130-137 22961735-6 2012 The single subset distinguishing best between active pulmonary TB and high TB exposure was CD154(+) /TNF-alpha(+) / IFN-gamma(-) /IL-2(-) /degranulation(-) (AUROC 0.90). Terbium 75-77 interleukin 2 Homo sapiens 130-137 23071578-5 2012 The ratio between secreted IFN-gamma/IL-10 and IL-2/IL-10 was significantly lower in TB-IRIS patients in whom the cause of TB was a drug-resistant strain compared to those with a fully sensitive strain (p = 0.02). Terbium 85-87 interleukin 2 Homo sapiens 47-51 23071578-5 2012 The ratio between secreted IFN-gamma/IL-10 and IL-2/IL-10 was significantly lower in TB-IRIS patients in whom the cause of TB was a drug-resistant strain compared to those with a fully sensitive strain (p = 0.02). Terbium 123-125 interleukin 2 Homo sapiens 47-51